Progress of myeloid-derived suppressor cells in myelodysplastic syndrome
10.3760/cma.j.cn115356-20200611-00158
- VernacularTitle:髓源性抑制细胞在骨髓增生异常综合征中的研究进展
- Author:
Xingang LI
;
Hongxia MA
;
Xudong WEI
- From:
Journal of Leukemia & Lymphoma
2021;30(1):61-64
- CountryChina
- Language:Chinese
-
Abstract:
Myelodysplastic syndrome (MDS) is characterized by dysplastic and ineffective hematopoiesis that can result from aberrant expansion and activation of myeloid-derived suppressor cells (MDSC) within the bone marrow microenvironment. The proliferation and activation of MDSC lead to the dysfunction and depletion of natural killer cells and CD8 + T cells, and the recruitment of inflammatory cells and factors leads to the further accumulation of genetic abnormalities in MDS patients, leading to the progression of MDS. The accumulation of inflammatory cytokines in the tumor environment induces the expression of programmed death receptor 1 (PD-1) in hematopoietic stem cells and hematopoietic progenitor cells and the overexpression of programmed death receptor ligand 1 (PD-L1) in MDSC, and the interaction of PD-1/PD-L1 leads to the apoptosis of MDS hematopoietic progenitor cells and ineffective hematopoiesis. The experiments and clinical studies targeting MDSC have confirmed that correcting or reversing the bone marrow microenvironment of immune disorders in MDS is a therapeutic strategy to restore effective hematopoietic function.
